TrialCancer chemotherapy and pharmacology2013

Phase I study evaluating the combination of lapatinib (a Her2/Neu and EGFR inhibitor) and everolimus (an mTOR inhibitor) in patients with advanced cancers: South West Oncology Group (SWOG) Study S0528.

Shirish M Gadgeel et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.